학술논문
1246P A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients
Document Type
Abstract
Author
Source
In Annals of Oncology September 2021 32 Supplement 5:S981-S981
Subject
Language
ISSN
0923-7534